Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

Search Results

Showing Results for subcutaneous levodopa

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

At EAN 2025, Prof. K. Ray Chaudhuri shares insights into cutting-edge Parkinson's drug delivery methods, the future of biomarker-driven care, advances in managing sleep disturbances, and the vital role of lifestyle modifications in optimizing patient outcomes.

Mark CompleteCompleted
BookmarkBookmarked

The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.

Coverage from: EAN 2024

Explore ground-breaking advancements in the treatment of movement disorders in this insightful interview with Prof. K. Ray Chaudhuri, who shares his key takeaways from the 10th Congress of the European Academy of Neurology meeting in Helsinki. He discusses promising new therapies, personalized care approaches, and significant research on the staging of Parkinson's. Additionally, Prof. Chaudhuri emphasizes the importance of holistic treatment, stepped-care strategies, remote management, and the potential of wearable technology in improving patient outcomes, bringing his wealth of knowledge and insights to touchNEUROLOGY

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Neurology. We are excited to present a collection of articles that showcase the latest advancements and diverse perspectives in neurological research and treatment. This issue features insightful reviews and editorials from esteemed ...

Mark CompleteCompleted
BookmarkBookmarked
Angelo Antonini, Valentina D'Onofrio, Andrea Guerra

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of nigrostriatal dopaminergic neurons, with its incidence increasing globally.1 With disease progression, the benefit from medications shortens, and symptom control becomes strictly dependent on peripheral levodopa (...

Mark CompleteCompleted
BookmarkBookmarked
C Warren Olanow, Werner Poewe, Olivier Rascol

Phenomenology and clinical significance of OFF episodes in Parkinson’s disease Werner Poewe Department of Neurology, Innsbruck Medical University, Innsbruck, Austria The emergence of OFF episodes in Parkinson's disease (PD) marks the transition from the so-called ‘honeymoon’ period of good ...

Mark CompleteCompleted
BookmarkBookmarked

The burdens of Parkinson’s disease (PD) are undeniably serious and increasing while various unmet needs remain, especially the absence of disease-modifying therapies and the difficulty of finding new treatments that are effective in patients.1–7 Although this seems a discouraging ...

Mark CompleteCompleted
BookmarkBookmarked

Optimising the effect of dopaminergic treatment in Parkinson’s disease Presented by: Werner Poewe Department of Neurology, Medical University of Innsbruck, Austria In considering dopaminergic treatment of Parkinson’s disease (PD), one must consider dopaminergic drug targets, effect sizes of ...

Mark CompleteCompleted
BookmarkBookmarked

Introduction Safinamide is an innovative therapeutic option in Parkinson’s disease (PD), with a unique dual mode of action that goes beyond dopaminergic pathways.1 Its mechanisms of action include monoamine oxidase-B (MAO-B) and dopamine reuptake inhibition, activity-dependent sodium-channel inhibition, and ...

Mark CompleteCompleted
BookmarkBookmarked

Introduction Andrew Lees The National Hospital for Neurology and Neurosurgery and Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, UK Professor Lees introduced the symposium by highlighting that there had been several significant landmark ...

Coverage from: AAN Highlights

  Prof. Stuart Isaacson, Editorial Board member for US Neurology, catches up with us to talk about his recent study of apomorphine subcutaneous injection to combat delayed onset of morning levodopa dose, in patients with morning akinesia. He also briefly ...

Mark CompleteCompleted
BookmarkBookmarked

Professor Trenkwalder considered that the challenge of how to enhance outcomes for patients was a key focus of clinical care for all clinicians who treated patients with Parkinson’s disease (PD). However, despite receiving multiple medications, many patients with PD ...

Mark CompleteCompleted
BookmarkBookmarked

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, with a prevalence that increases with age: 41 in 100,000 in the age group 40–49, rising to 1,903 in 100,000 in those aged over 80 years.1 PD is characterised by striatal dopamine deficiency resulting from progressive degeneration ...

Coverage from: MDS Highlights

  Fabrizio Stocchi discusses how OFF periods develop during Levodopa therapy and the use of apomorphine therapy to address these OFF periods. FILMED AT THE INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS (IPMDS), JUNE 2016 CAN YOU EXPLAIN HOW ...

Mark CompleteCompleted
BookmarkBookmarked

Restless legs syndrome (RLS), or Willis–Ekbom disease (WED), is a sensorimotor disorder having well-known standardised diagnostic criteria1 that have been revised recently by the International Restless Legs Syndrome Study Group.2 The genetic basis of RLS has not been definitively ...

Mark CompleteCompleted
BookmarkBookmarked

Restless legs syndrome (RLS), or Willis–Ekbom disease (WED), is a sensorimotor disorder having well-known standardised diagnostic criteria1 that have been revised recently by the International Restless Legs Syndrome Study Group.2 The genetic basis of RLS has not been definitively ...

Mark CompleteCompleted
BookmarkBookmarked

Introduction to Apomorphine and its Role in the Treatment of Parkinson’s DiseaseAndrew LeesProfessor of Neurology, National Hospital for Neurology and Neurosurgery, London. Apomorphine is a highly-potent dopamine agonist (DA) that, unlike other clinically available compounds in this class, selectively ...

Load More...
Close Popup